Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

How non-alcoholic fatty liver disease and cirrhosis affect the heart.

Hepatology international·2023

Same author

Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis.

Acta oncologica (Stockholm, Sweden)·2023

Same author

The effect of BRAF<sup>V600E</sup> mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study.

Journal of geriatric oncology·2023

Same author

Primary anastomosis and suturing combined with vacuum-assisted abdominal closure in patients with secondary peritonitis due to perforation of the small intestine: a retrospective study.

BMC surgery·2023

Same author

Suboptimal diagnostic accuracy of ultrasound and CT for compensated cirrhosis: Evidence from prospective cohort studies.

Hepatology communications·2023

Same author

Longitudinal bidirectional associations between diabetic retinopathy and diagnosed depression: Results from a Danish nationwide registry-based cohort study.

Journal of diabetes and its complications·2023

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Cirrhotic cardiomyopathy.

Søren Møller¹, Jens H Henriksen

¹Department of Clinical Physiology and Nuclear Medicine, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark. soeren.moeller@hvh.regionh.dk

Journal of Hepatology

|May 14, 2010

Summary

Cirrhotic cardiomyopathy is a latent cardiac dysfunction in cirrhosis patients, characterized by reduced contractility and electrical abnormalities. Early recognition and supportive care are crucial for managing this condition.

Area of Science:

Cardiology
Hepatology
Internal Medicine

Background:

Increased cardiac output in cirrhosis patients was noted over 50 years ago.
Latent cardiac dysfunction, termed cirrhotic cardiomyopathy, involves reduced contractility, systolic/diastolic dysfunction, and electrophysiological abnormalities.

Purpose of the Study:

To review the mechanisms, clinical presentation, and management of cirrhotic cardiomyopathy.
To highlight the implications of systolic dysfunction in advanced liver disease and renal failure.

Main Methods:

Review of experimental studies and clinical observations.
Analysis of mechanisms including beta-adrenergic signaling, nitric oxide, and cannabinoid receptors.

Main Results:

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Systolic dysfunction is revealed by stress and implicated in renal failure.
Diastolic dysfunction involves delayed filling, hypertrophy, edema, and altered collagen.
Prolonged QT interval occurs in ~50% of patients, potentially responsive to beta-blockers.

Conclusions:

No specific therapy exists; supportive care targeting cardiac dysfunction is recommended.
Future research should focus on prevalence, impact on survival, and novel treatments.